We evaluated the immunogenicity and safety of a 4-dose infant/toddler regimen of MenACWY-CRM given at 2 , 4 , 6 , and 12 months of age concomitantly with pentavalent diphtheria-tetanus-acellular pertussis-Hemophilus influenzae type b-inactivated poliovirus-combination vaccine ( DTaP-IPV/Hib ) , hepatitis B vaccine ( HBV ) , 7 - or 13-valent conjugate pneumococcal vaccine ( PCV ) , and measles , mumps , and rubella vaccine ( MMR ) .